Company research
MANGOCEUTICALS, INC.
CIK 1938046Updated Nov 9, 2026
SecurityMGRX · NASDAQ · equity
Name history
MANGOCEUTICALS, INC. · through Nov 6, 2026
MGRX price & chart
Loading TradingView…
NASDAQ:MGRX on TradingView ↗In the news
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds ↗
Recent filings
Submission of Matters to a Vote of Security Holders · Shareholder Director Nominations · Other Events
Items 5.07, 5.08, 8.01
PRE 14A filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
4 filing
Show 5 more recent filings
SCHEDULE 13D/A - filed by Cohen Jacob D. regarding MANGOCEUTICALS, INC.
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.01, 3.02, 7.01, 9.01
Termination of a Material Definitive Agreement
Items 1.02, 9.01
10-Q filing
425 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 16,531,802Source | 14,792,041Source | 14,172,795Source | 20,842,828Source | 15,237,827Source | 14,449,223Source | 21,753,857Source | 301,447Source | 16,089,573Source | 15,370,511Source | 1,050,793Source | 1,003,287Source |
| Property, Plant and Equipment, NetUSD | 2,049Source | 3,061Source | 1,292Source | 2,304Source | 3,313Source | 1,544Source | 2,556Source | 89,905Source | 1,794Source | 2,806Source | 96,129Source | 117,499Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 15,920,319Source | 14,610,000Source | 13,646,570Source | 20,694,893Source | 14,610,000Source | 13,941,146Source | 21,530,875Source | — | 14,232,484Source | 15,232,617Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 481,281Source | 73,912Source | 228,688Source | 101,019Source | 490,243Source | 174,562Source | 76,496Source | 15,305Source | 1,486,338Source | 58,653Source | 739,006Source | 682,860Source |
| Inventory, NetUSD | — | 13,213Source | — | — | 14,019Source | — | — | 14,452Source | — | — | 18,501Source | — |
| Assets, CurrentUSD | 598,223Source | 104,067Source | 245,687Source | 117,961Source | 517,561Source | 212,472Source | 176,652Source | 89,808Source | 1,547,434Source | 75,595Source | 818,460Source | 694,605Source |
| Operating Lease, Right-of-Use AssetUSD | 11,211Source | 74,913Source | 279,246Source | 27,670Source | 90,011Source | 294,061Source | 43,774Source | 104,792Source | 307,861Source | 59,493Source | 119,262Source | 174,241Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 804,275Source | 1,403,549Source | 1,648,969Source | 1,600,945Source | 1,408,382Source | 974,571Source | 1,503,196Source | 1,259,915Source | 890,568Source | 1,425,463Source | 276,039Source | 389,257Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,389Source | 213Source | 1,803Source | 1,065Source | 2,913Source | 1,698Source | 715Source | 2,362Source | 1,589Source | 325Source | 2,142Source | 1,337Source |
| Additional Paid in CapitalUSD | 53,283,483Source | 31,592,347Source | 57,568,236Source | 50,794,020Source | 30,300,213Source | 57,203,924Source | 45,868,946Source | 12,635,030Source | 55,524,812Source | 35,587,858Source | 12,000,785Source | 2,628,449Source |
| Retained Earnings (Accumulated Deficit)USD | -37,877,913Source | -17,985,966Source | -45,363,283Source | -31,649,804Source | -15,986,733Source | -44,050,630Source | -25,939,986Source | -13,595,754Source | -40,647,480Source | -20,806,595Source | -11,228,173Source | -2,015,756Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,079Source | -1,663Source | -5,198Source | -2,034Source | -1,166Source | -3,193Source | -2,221Source | -70Source | -2,760Source | -9,845Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 15,729,266Source | 13,389,329Source | 12,525,944Source | 19,243,064Source | 13,829,821Source | 13,476,185Source | 20,251,840Source | -958,432Source | 15,200,547Source | 13,946,129Source | 774,754Source | 614,030Source |
| Liabilities and EquityUSD | 16,531,802Source | 14,792,041Source | 14,172,795Source | 20,842,828Source | 15,237,827Source | 14,449,223Source | 21,753,857Source | 301,447Source | 16,089,573Source | 15,370,511Source | 1,050,793Source | 1,003,287Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 804,275Source | 1,391,382Source | 1,398,063Source | 1,600,945Source | 1,378,265Source | 737,606Source | 1,503,196Source | 1,212,202Source | 890,568Source | 1,425,463Source | 211,078Source | 260,577Source |
| Operating Lease, Liability, CurrentUSD | 12,167Source | 69,340Source | 28,301Source | 30,117Source | 67,428Source | 57,058Source | 47,713Source | 65,554Source | 307,823Source | 64,962Source | 63,718Source | 56,725Source |
| Operating Lease, Liability, NoncurrentUSD | — | 12,167Source | 250,906Source | — | 30,117Source | 236,965Source | — | 47,713Source | — | — | 64,961Source | 128,680Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,739Source | -837Source | -2,118Source | -1,181Source | -376Source | -1,533Source | -1,179Source | -36Source | -1,542Source | -1,081Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -7,618,776Source | -1,999,694Source | -1,312,931Source | -5,415,820Source | -3,403,141Source | -4,839,489Source | -20,643,455Source | -8,707,226Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 250Source | — | 9,936Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,090,114Source | 50,979Source | 1,168,280Source | 248,682Source | 624,463Source | 234,088Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | — | 18,501Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,311,343Source | -2,274,781Source | -5,850,255Source | -4,863,776Source | -6,997,375Source | -1,346,518Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 65,000Source | -3,519Source | -43,102Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 3,519Source | 43,102Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 2,285,000Source | 7,270,855Source | 4,128,268Source | 7,057,040Source | 2,049,930Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | 56,146Source | 660,310Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 481,281Source | 73,912Source | 228,688Source | 101,019Source | 174,562Source | 76,496Source | 1,486,338Source | 58,653Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 37,978Source | 50,979Source | — | 248,682Source | 624,463Source | 82,267Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 276,815Source | 276,815Source | 1,122,639Source | 721,533Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 250Source | 250Source | 1,012Source | 9,936Source | 24,889Source | 3,863Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | -18,387Source | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | — | 18,387Source | — | 18,387Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | -125,624Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | -125,625Source | — | — | -19,388Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 311,379Source | 523,855Source | 256,095Source | 1,245,360Source | 1,054,122Source | 1,542,444Source | 3,756,373Source | 3,000,571Source | 3,319,417Source | 1,643,572Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 1,239,942Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 75,850Source | — | — | 21,700Source | — | -13,700Source | 103,513Source | 13,700Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 0Source | 0Source | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,618,218Source | -1,999,233Source | -1,312,653Source | -5,415,818Source | -3,403,150Source | -4,839,391Source | -20,642,994Source | -8,706,145Source | -9,212,417Source | -1,998,055Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -558Source | -461Source | -278Source | -2Source | 9Source | -98Source | -461Source | -1,081Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,912,218Source | -2,293,233Source | -1,606,653Source | -5,709,818Source | -3,697,150Source | -5,133,391Source | -21,818,994Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -75,850Source | -241,620Source | -279,891Source | -147,325Source | -276,815Source | -263,115Source | -2,611,106Source | -735,233Source | 6,473Source | -6,473Source |
| Operating ExpensesUSD | — | — | 7,593,825Source | 1,840,745Source | 1,077,255Source | 5,358,443Source | 3,155,327Source | 4,638,438Source | 18,282,735Source | 8,351,957Source | 9,650,391Source | 1,996,432Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 655,000Source | 4,625,355Source | 1,328,268Source | 6,200,000Source | 2,000,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 84,246Source | 133,368Source | 68,757Source | 168,109Source | 67,864Source | 109,306Source | 456,021Source | 615,873Source | 731,493Source | 8,939Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -7,542,926Source | -1,758,074Source | -1,033,040Source | -5,268,495Source | -3,126,326Source | -4,576,374Source | -18,032,349Source | -7,971,993Source | -9,218,890Source | -1,991,582Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -7,618,776Source | -1,999,694Source | -1,312,931Source | -5,415,820Source | -3,403,141Source | -4,839,489Source | -20,643,455Source | -8,707,226Source | -9,212,417Source | -1,998,055Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -558Source | -461Source | -278Source | -2Source | 9Source | -98Source | -461Source | -1,081Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,618,218Source | -1,999,233Source | -1,312,653Source | -5,415,818Source | -3,403,150Source | -4,839,391Source | -20,642,994Source | -8,706,145Source | -9,212,417Source | -1,998,055Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.69Source | -1.14Source | -0.09Source | -0.57Source | -0.22Source | -1.12Source | -2.17Source | -4.84Source | -0.57Source | -0.19Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.69Source | -1.14Source | -0.09Source | -0.57Source | -0.22Source | -1.12Source | -2.17Source | -4.84Source | -0.57Source | -0.19Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 11,524,275Source | 2,013,848Source | 17,119,619Source | 9,983,376Source | 16,481,607Source | 4,593,062Source | 10,071,609Source | 1,978,966Source | 16,113,029Source | 10,798,083Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 11,524,275Source | 2,013,848Source | 17,119,619Source | 9,983,376Source | 16,481,607Source | 4,593,062Source | 10,071,609Source | 1,978,966Source | 16,113,029Source | 10,798,083Source |
| Interest Expense (non-operating)USD | — | — | 75,850Source | — | — | 21,700Source | — | -13,700Source | 103,513Source | 13,700Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 276,815Source | 276,815Source | 1,122,639Source | 721,533Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | -125,624Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 311,379Source | 523,855Source | 256,095Source | 1,245,360Source | 1,054,122Source | 1,542,444Source | 3,756,373Source | 3,000,571Source | 3,319,417Source | 1,643,572Source |
| Gross ProfitUSD | — | — | 50,899Source | 82,671Source | 44,215Source | 89,948Source | 29,001Source | 62,064Source | 250,386Source | 379,964Source | 431,501Source | 4,850Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 6,473Source |
| Labor and Related ExpenseUSD | — | — | 542,420Source | 242,941Source | 427,298Source | 628,343Source | 346,860Source | 349,783Source | 1,348,051Source | 1,063,781Source | 977,890Source | — |
| Marketing and Advertising ExpenseUSD | — | — | 104,914Source | 251,330Source | 301,445Source | 258,295Source | 94,073Source | 281,732Source | 822,860Source | 1,478,663Source | 2,097,505Source | 352,860Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,912,218Source | -2,293,233Source | -1,606,653Source | -5,709,818Source | -3,697,150Source | -5,133,391Source | -21,818,994Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -75,850Source | -241,620Source | -279,891Source | -147,325Source | -276,815Source | -263,115Source | -2,611,106Source | -735,233Source | 6,473Source | -6,473Source |
| Operating ExpensesUSD | — | — | 7,593,825Source | 1,840,745Source | 1,077,255Source | 5,358,443Source | 3,155,327Source | 4,638,438Source | 18,282,735Source | 8,351,957Source | 9,650,391Source | 1,996,432Source |
Offerings
Registration 333-292711
Filing attachments
ex4-1.htm · 8-K · 2026-10-09
Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT MANGOCEUTICALS, INC. Warrant Issue Shares: 657,000 Date: October 9, 2026 THIS COMMON STOCK PURCHASE WARRANT (this “ Warrant ”) certifies that, for value received, GHS Investments or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (the “ Initial Exercise Date ”) and on or prior to 5:00 p.m. …
Read attachment ↗ex99-1.htm · 8-K · 2026-10-09
Exhibit 99.1 Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX / October 9, 2026 / Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and Peac…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-01
Exhibit 99.1 Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock DALLAS, TEXAS, October 1, 2026 (GLOBE NEWSWIRE) - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling health and we…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination Dallas, Texas - August 4, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in …
Read attachment ↗ex99-1.htm · 425 · 2026-07-30
Exhibit 99.1 Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology Business Combination Agreement to Bring Nuclea’s Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS - July 30, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that it has entered into a definitive business combination agreement …
Read attachment ↗ex99-1.htm · 8-K · 2026-07-30
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology Business Combination Agreement to Bring Nuclea’s Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS - July 30, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that it has entered into a definitiv…
Read attachment ↗